NEWS RELEASE

Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”), trading on the
Canadian Securities Exchange (“CSE”) under the trading Symbol “NVG” and on
Deutsche Boerse, Frankfurt under the trading Symbol 3NVN, is pleased to
announce that following an internal Listing Application Review, the Canadian
Securities Exchange (the “CSE”) has approved the fundamental change of Nass
Valley Gateway Ltd. for listing subject to the following conditions:

Completion of the acquisition (the “Acquisition”) of
Advanced Bioceuticals Limited (“ABL”);

Completion of any and all outstanding CSE application
documentation and payment of fees pursuant to the Policies of the CSE.

A date for trading will be determined upon confirmation of the conditions
being met.

Pursuant to the Acquisition, the Company is acquiring 100% ownership
interest in ABL and its wholly owned subsidiary Pro-Thotics Technology Inc. (“PTI”). The Definitive
Acquisition and Share Exchange Agreement
was executed on March 22, 2018. The transaction is arm’s length and no finders’
fees are being paid. The Company will be issuing an aggregate of 400,000,000
shares of the Company at a price of $0.10 per share which amounts to 89.27% of
the fully paid and non-assessable common shares of the Company’s when the
Acquisition is completed. Upon completion of the transaction, ABL and PTI will become two wholly
owned subsidiaries of Nass Valley. The to be issued shares will be subject to
an escrow agreement in accordance to the rules of the CSE. The
transaction is a reverse take-over.

As wholly owned subsidiaries of Nass Valley, ABL
will continue to focus on
commencing the sale of hemp based cannabidiol (CBD) with zero
Tetrahydrocannabinol (THC) content products including CBD infused skin, bath,
and body care products (the “ABL-Business”) and PTI will continue to focus on
expanding the sale of Durable Medical Equipment (“DME” or “PTI-Business”).

PTI’s business was
mostly concentrated in the states of New York, New Jersey, and Florida for last
25 years serving patients throughout the US. During PTI’s 25-year history,
200,000 patients located throughout the U.S. and Puerto Rico were provided
relief from pain and medical issues through the purchase of PTI’s DME products
as well as establishing a solid database of satisfied patients seeking wellness
from pain relief.

Nass Valley is
determined to expand upon this pain relief concept through its ABL-Business and
to aggressively focus on the hemp based CBD marketplace as well as well as
expanding the sale of the PTI-Business on national basis.

Dieter Peter, President & CEO, commented:
“This transaction places Nass Valley in a strong strategic position to be at
the forefront of a new and innovative industry relating to the development and
sale of its CBD based products. I am therefore especially delighted that ABL’s
young and experienced management team as major future shareholders agreed to
join Nass Valley’s future management and Board of Directors and will bring
tremendous value to the company’s future growing with their marketing and
operational experience including financial management and risk estimations.”

Forward
Looking Statements

Statements in
this news release that are forward-looking statements are subject to various
risks and uncertainties concerning the specific factors disclosed here and
elsewhere in Nass Valley’s periodic filings with Canadian securities
regulators. When used in this news release, words such as “will, could,
plan, estimate, expect, intend, may, potential, believe, should, aware”
and similar expressions, are forward-looking statements.

Although Nass Valley has attempted to
identify important factors that could cause actual results, performance or
achievements to differ materially from those contained in the forward-looking
statements, there can be other factors that cause results, performance or
achievements not to be as anticipated, estimated or intended, including, but
not limited to: dependence on obtaining regulatory approvals; investing in
target companies or projects which have limited operating history or when very
limited due diligence was performed or may be engaged in activities currently
considered illegal under US Federal laws; change in laws; limited operating
history; reliance on management; requirements for additional financing;

competition; hindering market growth and
state adoption due to inconsistent public opinion and perception of the medical-use
and adult-use marijuana industry; and regulatory or political change.

There can be no
assurance that such information will prove to be accurate or that management’s
expectations or estimates of future developments, circumstances or results will
materialize. As a result of these risks and uncertainties, the results or
events predicted in these forward-looking statements may differ materially from
actual results or events.

Accordingly,
readers should not place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the date of this
release. Nass Valley disclaims any intention or obligation to update or revise
such information, except as required by applicable law, and Nass Valley does
not assume any liability for disclosure relating to any other company mentioned
herein.

For further
information please contact:

Dieter
Peter, President & CEO

Phone: 604-617-6794

Neither the
CSE nor its Regulation Services Provider has reviewed or accepts responsibility
for the adequacy or accuracy of the contents of this news release.